21 November 2019
A settlement has been reached in the landmark legal case of Aoife Bennett, who developed narcolepsy following the administration of the Pandemrix H1N1 influenza vaccine. To avoid a formal judicial determination of liability, the defendants opted for a settlement agreement that includes no admission of fault.
While the specific financial terms of the agreement remain confidential, the defendants, including the Irish State and GlaxoSmithKline (GSK), have agreed to cover the plaintiff’s legal costs, which are estimated to exceed €2 million. For Ms. Bennett, this concludes a ten-year legal battle against the Irish healthcare system, which has faced significant criticism for its perceived failure to adequately address vaccine-related injuries.
Approximately 100 other individuals in Ireland, who reported similar adverse effects and were awaiting a legal precedent to join the litigation, must now decide their next steps. Unless a comprehensive national compensation scheme is established for all affected parties, further individual lawsuits against the Department of Health and GSK are expected.
Ireland’s approach follows a pattern seen in other nations, including Sweden, Finland, the Netherlands, and the United Kingdom, where governments have provided compensation to victims without formally admitting liability. The Pandemrix case underscores significant concerns regarding the professional management of the 2009 pandemic vaccination campaign, with many viewing the settlement as an implicit acknowledgement of systemic shortcomings in the vaccine's deployment and monitoring.